药物辅助治疗对阿片类药物使用者死亡率影响的系统综述与荟萃分析
结果显示,接受MAT期间全因与过量死亡粗死亡率均低于停药后及未治疗期;未治疗者全因死亡风险为接受MAT者的2.56倍,过量死亡风险为8.10倍。提高MAT覆盖率和依从性及治疗后随访对降低死亡率至关重要。
要点
- 接受MAT期间全因粗死亡率为0.92/100人年,未治疗期为4.89/100人年。
- 未治疗者全因死亡风险为接受MAT者的2.56倍,过量死亡风险为8.10倍。
- MAT维持超过1年的全因粗死亡率低于维持≤1年者(1.62 vs. 5.31/100人年)。
核心结论
- MAT与OUD患者全因及过量死亡风险降低相关,未治疗和停药后死亡风险更高。
- 提高MAT覆盖率、依从性及治疗后随访对降低死亡率至关重要。
- 长效纳曲酮在预防OUD患者过早死亡方面显示出积极优势。
研究设计与样本
- 采用随机效应模型、亚组分析和荟萃回归汇总粗死亡率(CMR)与相对风险(RR)。
主要发现
- 接受MAT期间全因CMR为0.92/100人年(95%CI:0.79-1.04),停药后为1.69(1.47-1.91),未治疗期为4.89(3.54-6.23)。
- 接受MAT期间过量CMR为0.24/100人年(0.20-0.28),停药后为0.68(0.55-0.80),未治疗期为2.43(1.72-3.15)。
- 与接受MAT者相比,未治疗者全因死亡RR为2.56(1.72-3.80),过量死亡RR为8.10(4.48-14.66)。
- 与接受MAT者相比,出院者全因死亡RR为2.33(2.02-2.67),过量死亡RR为3.09(2.37-4.01)。
- 美沙酮或丁丙诺啡替代治疗期间及之后全因CMR分别为0.93(0.76-1.10)和1.79(1.47-2.10);纳曲酮拮抗剂治疗分别为0.26(0-0.59)和1.97(0-5.18)。
关键数值与推荐
- MAT维持超过1年的全因CMR为1.62(1.31-1.93),维持≤1年为5.31(-0.09-10.71)。
临床怎么用
- 对OUD患者应扩大MAT覆盖并提高依从性,减少未治疗与治疗后脱随访导致的死亡风险。
- 关注停药后死亡风险升高,加强MAT后随访与衔接管理。
- 可考虑长效纳曲酮用于预防OUD患者过早死亡。
局限性
- 纳入研究均为队列研究,可能存在混杂与异质性。
- 部分亚组(如纳曲酮治疗、维持时间)置信区间宽或含负值,估计不精确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Opioid use disorder (OUD) is associated with a high risk of premature death. Medication-assisted treatment (MAT) is the primary treatment for opioid dependence. We comprehensively assessed the effects of different MAT-related characteristics on mortality among those with OUD by a systematic review and meta-analysis. The all-cause and overdose crude mortality rates (CMRs) and relative risks (RRs) by treatment status, different type, period, and dose of medication, and retention time were pooled using random effects, subgroup analysis, and meta-regression. Thirty cohort studies involving 370,611 participants (1,378,815 person-years) were eligible in the meta-analysis. From 21 studies, the pooled all-cause CMRs were 0.92 per 100 person-years (95% CI: 0.79-1.04) while receiving MAT, 1.69 (1.47-1.91) after cessation, and 4.89 (3.54-6.23) for untreated period. Based on 16 studies, the pooled overdose CMRs were 0.24 (0.20-0.28) while receiving MAT, 0.68 (0.55-0.80) after cessation of MAT, and 2.43 (1.72-3.15) for untreated period. Compared with patients receiving MAT, untreated participants had higher risk of all-cause mortality (RR 2.56 [95% CI: 1.72-3.80]) and overdose mortality (8.10 [4.48-14.66]), and discharged participants had higher risk of all-cause death (2.33 [2.02-2.67]) and overdose death (3.09 [2.37-4.01]). The all-cause CMRs during and after opioid substitution treatment with methadone or buprenorphine were 0.93 (0.76-1.10) and 1.79 (1.47-2.10), and corresponding estimate for antagonist naltrexone treatment were 0.26 (0-0.59) and 1.97 (0-5.18), respectively. Retention in MAT of over 1-year was associated with a lower mortality rate than that with retention ≤1 year (1.62, 1.31-1.93 vs. 5.31, -0.09-10.71). Improved coverage and adherence to MAT and post-treatment follow-up are crucial to reduce the mortality. Long-acting naltrexone showed positive advantage on prevention of premature death among persons with OUD.
引用
- Ma J, Bao YP, Wang RJ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018. PMID: 29934549. doi:10.1038/s41380-018-0094-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。